Danica Pension Livsforsikringsaktieselskab Takes Position in IQVIA Holdings Inc. $IQV

Danica Pension Livsforsikringsaktieselskab bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 211,164 shares of the medical research company’s stock, valued at approximately $36,012,000. Danica Pension Livsforsikringsaktieselskab owned about 0.13% of IQVIA as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. J. Safra Sarasin Holding AG lifted its holdings in IQVIA by 174.3% in the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock worth $2,891,000 after buying an additional 8,151 shares during the period. CWM LLC increased its stake in shares of IQVIA by 23.9% during the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after buying an additional 10,762 shares during the period. Franklin Street Advisors Inc. NC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $15,724,000. HF Advisory Group LLC raised its holdings in shares of IQVIA by 1,791.6% during the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock valued at $34,852,000 after acquiring an additional 146,444 shares in the last quarter. Finally, Calamos Advisors LLC lifted its stake in IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after acquiring an additional 137,441 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Evercore reissued an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Mizuho raised their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Trading Down 1.2%

NYSE:IQV opened at $201.40 on Wednesday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $247.04. The company’s 50-day simple moving average is $186.19 and its 200 day simple moving average is $187.55. The firm has a market capitalization of $33.61 billion, a P/E ratio of 24.96, a PEG ratio of 1.83 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the business earned $2.70 earnings per share. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has approved a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.